Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$4.41
$1.35
$50.10
$3.66M1.04227,964 shs650,294 shs
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$0.35
$0.03
$3.17
$3.50M0.497.01 million shs61.02 million shs
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
$1.88
$1.89
$0.58
$5.87
$98.94M0.752.46 million shs169,314 shs
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.02
-3.8%
$0.73
$0.37
$1.15
$242.06M1.61.61 million shs1.88 million shs
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$3.41
+7.2%
$3.41
$1.98
$6.30
$524.84M1.1726,999 shs3,000 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%-92.21%
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
0.00%0.00%0.00%0.00%-94.47%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
0.00%0.00%0.00%0.00%0.00%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-3.77%+0.99%+36.89%+117.11%+14.22%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.00%0.00%0.00%0.00%+72.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.2629 of 5 stars
3.80.00.00.00.60.00.0
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/AN/AN/AN/A
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
2.0429 of 5 stars
3.51.00.00.00.03.30.6
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.3212 of 5 stars
1.10.00.00.01.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3.50
Strong Buy$6.00∞ Upside
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
2.50
Moderate Buy$2.17∞ Upside
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
0.00
N/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3.00
Buy$4.20311.76% Upside
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
2.17
Hold$1.33-60.90% Downside

Current Analyst Ratings Breakdown

Latest GRTS, JNCE, OPT, APTO, and LCTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
6/23/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$496K0.00N/AN/A$0.54 per share0.00
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
$82M1.21N/AN/A$3.54 per share0.53
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$9.50M24.52N/AN/A$0.35 per share2.91
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$120K4,373.61N/AN/A($0.56) per share-6.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/A
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$18.61M-$0.12N/AN/AN/A-169.57%-22.64%-15.27%8/6/2025 (Estimated)
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
-$220.24MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/A
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/AN/AN/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/AN/AN/AN/AN/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
1.05
1.05
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
1.83
2.54
2.54
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/A
8.37
8.37
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/A
3.82
3.82
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/A
1.57
N/A

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
48.46%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
80.66%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
62.47%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
55.95%

Insider Ownership

CompanyInsider Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.33%
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
4.61%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
6.92%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
26.80%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
312.14 million63.45 millionNo Data
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
190108.57 million111.84 millionOptionable
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
13752.63 million48.99 millionOptionable
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
60228.36 million167.16 millionNot Optionable
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
8153.91 million148.99 millionNot Optionable

Recent News About These Companies

Opthea (NASDAQ:OPT) Shares Gap Up - Here's Why
Opthea to lay off approximately 65% of company
Opthea Limited (CKDXF) was downgraded to a Sell Rating at Bell Potter
Opthea Ends Development of Sozinibercept in Wet AMD
Opthea terminates COAST trial, announces ShORe trial misses endpoint

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Gritstone bio stock logo

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Jounce Therapeutics stock logo

Jounce Therapeutics NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Lineage Cell Therapeutics stock logo

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.02 -0.04 (-3.77%)
Closing price 07/10/2025 04:10 PM Eastern
Extended Trading
$1.03 +0.01 (+1.47%)
As of 07/10/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Opthea stock logo

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)
As of 07/9/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.